NCT06764875 2026-03-09A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerAstraZenecaPhase 3 Recruiting840 enrolled